​

Opus Genetics (IRD) Stock Forecast, Price Target & Predictions

OverviewRevenueFinancialsChart

IRD Stock Forecast

Opus Genetics (IRD) stock forecast, based on 4 Wall Street analysts, predicts a 12-month average price target of $7.00, with a high of $7.00 and a low of $7.00. This represents a 243.14% increase from the last price of $2.04.

IRD Stock Rating

Opus Genetics stock's rating consensus is Buy, based on 4 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 4 0 4 Strong Sell Sell Hold Buy Strong Buy

IRD Price Target Upside V Benchmarks

TypeNameUpside
StockOpus Genetics243.14%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-11
Avg Price Target-$7.00$7.00
Last Closing Price$2.04$2.04$2.04
Upside/Downside-243.14%243.14%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Dec, 2518---9
Nov, 2516---7
Oct, 2513---4
Sep, 2513---4
Aug, 2513---4
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 25, 2025Piper Sandler$7.00$2.00250.00%243.14%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Dec 10, 2025B. RileyBuyinitialise
Nov 25, 2025Piper SandlerOverweightinitialise
Oct 29, 2025WedbushOutperforminitialise

Financial Forecast

EPS Forecast

Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$-0.46$-2.15-----
Avg Forecast$-0.30$-1.12$-0.95$-0.57$-0.53$-0.32$-0.16
High Forecast$-0.25$-0.96$-0.81$-0.24$-0.45$-0.27$-0.14
Low Forecast$-0.35$-1.30$-1.10$-0.89$-0.61$-0.37$-0.19
Surprise %53.33%91.96%-----

Revenue Forecast

$5M $17M $29M $41M $53M $65M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$19.05M$10.99M-----
Avg Forecast$22.68M$10.10M$14.92M$25.01M$31.30M$42.36M$55.00M
High Forecast$25.55M$11.38M$16.80M$31.47M$35.26M$47.72M$61.97M
Low Forecast$20.12M$8.96M$13.23M$19.26M$27.77M$37.59M$48.81M
Surprise %-15.99%8.83%-----

Net Income Forecast

$-60M $-48M $-36M $-24M $-12M $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$-9.99M$-57.53M-----
Avg Forecast$-7.95M$-30.19M$-25.48M$-15.09M$-14.15M$-8.55M$-4.27M
High Forecast$-6.78M$-25.54M$-21.55M$-6.36M$-11.97M$-7.30M$-3.65M
Low Forecast$-9.26M$-34.85M$-29.40M$-23.83M$-16.33M$-9.96M$-4.98M
Surprise %25.64%90.55%-----

IRD Forecast FAQ

Is Opus Genetics stock a buy?

Opus Genetics stock has a consensus rating of Buy, based on 4 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Opus Genetics is a favorable investment for most analysts.

What is Opus Genetics's price target?

Opus Genetics's price target, set by 4 Wall Street analysts, averages $7 over the next 12 months. The price target range spans from $7 at the low end to $7 at the high end, suggesting a potential 243.14% change from the previous closing price of $2.04.

How does Opus Genetics stock forecast compare to its benchmarks?

Opus Genetics's stock forecast shows a 243.14% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Opus Genetics over the past three months?

  • December 2025: 11.11% Strong Buy, 88.89% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • November 2025: 14.29% Strong Buy, 85.71% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • October 2025: 25.00% Strong Buy, 75.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Opus Genetics’s EPS forecast?

Opus Genetics's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.95, marking a -55.81% decrease from the reported $-2.15 in 2024. Estimates for the following years are $-0.57 in 2026, $-0.53 in 2027, $-0.32 in 2028, and $-0.16 in 2029.

What is Opus Genetics’s revenue forecast?

Opus Genetics's average annual revenue forecast for its fiscal year ending in December 2025 is $14.92M, reflecting a 35.69% increase from the reported $10.99M in 2024. The forecast for 2026 is $25.01M, followed by $31.3M for 2027, $42.36M for 2028, and $55M for 2029.

What is Opus Genetics’s net income forecast?

Opus Genetics's net income forecast for the fiscal year ending in December 2025 stands at $-25.475M, representing a -55.72% decrease from the reported $-57.532M in 2024. Projections indicate $-15.094M in 2026, $-14.153M in 2027, $-8.549M in 2028, and $-4.274M in 2029.